GenVec’s Board oversees and guides the Company’s management and its business. Committees support the role of the Board on issues that benefit from consideration by a smaller, more focused subset of Directors. The GenVec Board has a Nominating and Corporate Governance Committee, an Audit Committee and a Compensation Committee.
The Board of Directors has adopted and approved a charter for each of its standing committees.
The Board of Directors has affirmatively determined that each of the following directors is independent within the meaning of the NASDAQ director independence standards: Wayne T. Hockmeyer, Ph.D., Chairman of the Board, William N. Kelley, M.D., Stefan D. Loren, Ph.D. Quinterol J. Mallette, M.D., and Marc R. Schneebaum. The Board of Directors has also determined that the following director is not independent within the meaning of the NASDAQ director independence standards: Douglas J. Swirsky, the Company’s President and Chief Executive Officer. The Board has also determined that all standing committees of the Board of Directors are composed entirely of independent directors.
Communication with the Board
GenVec’s Stockholders may communicate with the Board of Directors or any member thereof by sending any communication, in writing, by certified mail, to GenVec’s Corporate Secretary:
910 Clopper Road
Gaithersburg, MD 20878